# Targeting p53 conformational defects to arrest carcinogenesis

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 · $83,115

## Abstract

PROJECT SUMMARY
This supplement extends the work proposed in the parental grant that is focused on targeting p53 protein
conformational defects for ovarian cancer prevention and treatment. Here, we will test the effects of the
administration of a p53 aggregation inhibitor on cancer development using an in vivo HGSOC model carrying
control p53 mutations. We will also investigate whether protein aggregation is a broader phenomenon influencing
ovarian cancer cell fitness using organoid models.

## Key facts

- **NIH application ID:** 10381311
- **Project number:** 3R01CA240718-03S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Alice Soragni
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $83,115
- **Award type:** 3
- **Project period:** 2019-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10381311

## Citation

> US National Institutes of Health, RePORTER application 10381311, Targeting p53 conformational defects to arrest carcinogenesis (3R01CA240718-03S1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10381311. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*